Back
Day Range
$235.75
$241.46
52-Week Range
$141.50
$251.71
Volume
6,454,367
50D / 200D Avg
$234.14
/
$194.58
Prev Close
$235.27
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (631 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 21.6 | 0.2 |
| P/B | 7.1 | 3.0 |
| ROE % | 35.0 | 3.6 |
| Net Margin % | 28.5 | 3.8 |
| Rev Growth 5Y % | 4.6 | 9.9 |
| D/E | 0.6 | 0.2 |
Analyst Price Target
Hold
$228.73
-4.7%
Low: $190.00
High: $265.00
Forward P/E
20.76
Forward EPS
$11.56
EPS Growth (est.)
+0.0%
Est. Revenue
100.63B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$16.71
$16.10 – $17.19
|
127.41B | 2 |
| FY2029 |
$15.06
$14.51 – $15.49
|
119.93B | 2 |
| FY2028 |
$13.73
$10.81 – $16.03
|
113.17B | 5 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-01-21 | $2.46 | $2.46 | 0.0% |
| 2025-10-14 | $2.76 | $2.80 | +1.4% |
| 2025-07-16 | $2.68 | $2.77 | +3.4% |
| 2025-04-15 | $2.58 | $2.77 | +7.4% |
| 2025-01-22 | $1.99 | $2.04 | +2.5% |
| 2024-10-15 | $2.21 | $2.42 | +9.5% |
| 2024-07-17 | $2.71 | $2.82 | +4.1% |
| 2024-04-16 | $2.64 | $2.71 | +2.7% |
Insider Trading Activity
Buy ratio (90d)
0.0%
13 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
sell | 4,075 | $247.87 | $1,010,070.25 |
| Feb 27, 2026 |
Decker Robert J
VP Corporate Controller
|
other | 8,150 | $115.67 | — |
| Feb 20, 2026 |
Schmid Timothy
EVP, WW Chair, MedTech
|
sell | 1,322 | $245.66 | $324,762.52 |
| Feb 9, 2026 |
Broadhurst Vanessa
EVP, Global Corp Affairs
|
grant | 8,594 | — | — |
| Feb 9, 2026 |
Decker Robert J
VP Corporate Controller
|
grant | 2,741 | — | — |
| Feb 6, 2026 |
Mulholland Kristen
EVP, Chief HR Officer
|
other | 14,585 | $101.87 | $1,946,404.15 |
| Nov 26, 2025 |
MORIKIS JOHN G
Director
|
buy | 1,250 | $206.15 | $257,687.50 |
| Sep 9, 2025 |
Woods Eugene A.
Director
|
grant | 211 | $178.07 | $37,572.77 |
| Jul 17, 2025 |
REED JOHN C
EVP, Innovative Medicine, R&D
|
sell | 19,137 | $163.55 | $3,129,829.56 |
| Jun 10, 2025 |
HEWSON MARILLYN A
Director
|
grant | 322 | $155.23 | $49,984.06 |
| Apr 24, 2025 |
WEINBERGER MARK A
Director
|
grant | 1,316 | — | — |
| Apr 24, 2025 |
McClellan Mark B.
Director
|
grant | 1,316 | — | — |
| Apr 24, 2025 |
Woods Eugene A.
Director
|
grant | 1,316 | — | — |
Dividend History
7 yr streakYield
0.02%
Payout Ratio
0.46%
Growth (3Y)
4.92%
Growth (5Y)
5.25%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Feb 24, 2026 | Mar 10, 2026 | $1.30 | 2.11% |
| Nov 25, 2025 | Dec 09, 2025 | $1.30 | 2.49% |
| Aug 26, 2025 | Sep 09, 2025 | $1.30 | 2.88% |
| May 27, 2025 | Jun 10, 2025 | $1.30 | 3.28% |
| Feb 18, 2025 | Mar 04, 2025 | $1.24 | 3.20% |
| Nov 26, 2024 | Dec 10, 2024 | $1.24 | 3.18% |
| Aug 27, 2024 | Sep 10, 2024 | $1.24 | 2.98% |
| May 20, 2024 | Jun 04, 2024 | $1.24 | 3.18% |
| Feb 16, 2024 | Mar 05, 2024 | $1.19 | 3.04% |
| Nov 20, 2023 | Dec 05, 2023 | $1.19 | 3.14% |
| Aug 25, 2023 | Sep 07, 2023 | $1.19 | 2.79% |
| May 22, 2023 | Jun 06, 2023 | $1.19 | 2.92% |
| Feb 17, 2023 | Mar 07, 2023 | $1.13 | 2.82% |
| Nov 21, 2022 | Dec 06, 2022 | $1.13 | 2.53% |
| Aug 22, 2022 | Sep 06, 2022 | $1.13 | 2.61% |
| May 23, 2022 | Jun 07, 2022 | $1.13 | 2.40% |
| Feb 18, 2022 | Mar 08, 2022 | $1.06 | 2.60% |
| Nov 22, 2021 | Dec 07, 2021 | $1.06 | 2.62% |
| Aug 23, 2021 | Sep 07, 2021 | $1.06 | 2.33% |
| May 24, 2021 | Jun 08, 2021 | $1.06 | 2.40% |
Key Takeaways
Revenue grew 4.58% annually over 5 years — modest growth
Earnings grew 90.56% over the past year
ROE of 35.03% indicates high profitability
Net margin of 28.46% shows strong profitability
Generating 19.70B in free cash flow
PEG of 0.21 suggests growth is underpriced
Growth
Revenue Growth (5Y)
4.58%
Revenue (1Y)6.05%
Earnings (1Y)90.56%
FCF Growth (3Y)3.90%
Quality
Return on Equity
35.03%
ROIC14.83%
Net Margin28.46%
Op. Margin27.17%
Safety
Debt / Equity
0.59
Current Ratio1.03
Interest Coverage26.36
Valuation
P/E Ratio
21.57
Forward P/E20.76
P/B Ratio7.09
EV/EBITDA23.69
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6.05% | Revenue Growth (3Y) | 5.17% |
| Earnings Growth (1Y) | 90.56% | Earnings Growth (3Y) | -12.68% |
| Revenue Growth (5Y) | 4.58% | Earnings Growth (5Y) | 6.45% |
| Profitability | |||
| Revenue (TTM) | 94.19B | Net Income (TTM) | 26.80B |
| ROE | 35.03% | ROA | 13.46% |
| Gross Margin | 72.78% | Operating Margin | 27.17% |
| Net Margin | 28.46% | Free Cash Flow (TTM) | 19.70B |
| ROIC | 14.83% | FCF Growth (3Y) | 3.90% |
| Safety | |||
| Debt / Equity | 0.59 | Current Ratio | 1.03 |
| Interest Coverage | 26.36 | ||
| Dividends | |||
| Dividend Yield | 0.02% | Payout Ratio | 0.46% |
| Dividend Growth (3Y) | 4.92% | Dividend Growth (5Y) | 5.25% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 21.57 | Forward P/E | 20.76 |
| P/B Ratio | 7.09 | P/S Ratio | 6.14 |
| PEG Ratio | 0.21 | Forward PEG | N/A |
| EV/EBITDA | 23.69 | Fwd EV/EBITDA | 18.27 |
| Forward P/S | 5.75 | Fwd Earnings Yield | 4.82% |
| FCF Yield | 3.41% | ||
| Market Cap | 578.21B | Enterprise Value | 606.43B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B |
| EPS (Diluted) | 11.03 | 5.79 | 13.72 | 6.73 | 7.81 |
| Gross Profit | 68.56B | 61.35B | 58.61B | 55.39B | 55.34B |
| Operating Income | 25.60B | 22.15B | 23.41B | 21.01B | 20.94B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B |
| Total Liabilities | 117.67B | 108.61B | 98.78B | 110.57B | 108.00B |
| Shareholders' Equity | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B |
| Cash & Equivalents | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B |
| Current Assets | 55.62B | 55.89B | 53.50B | 55.29B | 60.98B |
| Current Liabilities | 54.13B | 50.32B | 46.28B | 55.80B | 45.23B |